SVB Securities analyst Andrew Berens upgraded Incyte to Market Perform from Underperform with a $61 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INCY:
- BofA sees minimal near-term impact on Incyte from ruxolitinib ER CRL
- Incyte provides regulatory update on Ruxolitinib extended relief
- MacroGenics to receive $15M milestone following FDA approval of Zynyz
- Incyte announces FDA accelerated approval of Zynyz
- Incyte announces data from Phase 2b study evaluating Povorcitinib